AuraSense Therapeutics is a biopharmaceutical company developing first-in-class therapies based on Spherical Nucleic Acid (SNA™) gene regulation strategies. AST is leading the translation of SNA constructs as innovative medicines with a core focus on debilitating diseases. AuraSense Therapeutics' uniquely engineered SNA™ constructs possess unparalleled biocompatibility and versatility as therapeutics. They hold great promise for combating the most threatening diseases, including cancer, skin conditions and infection.
SNA™ constructs overcome one of the most difficult obstacles to gene regulation: safe and effective delivery into cells and tissues. SNA™ constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutics for the treatment of cancer or infectious disease.
SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. The Company's scientific founders and their developments have been the subject of over 80 national and international awards, over 550 publications, and over 940 patents and applications (247 issued). AuraSense Therapeutics is a subsidiary of AuraSense, LLC.
David Giljohann Named Among Top 40 Under 40 by Analytical Scientist
Google’s Newest Search: Cancer Cells
AuraSense Therapeutics Expands Leadership Team
AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer
Bill Gates among new backers of Skokie startup